Phase 2 Results for Investigational Ready-To-Use Botulinum Toxin

Galderma Investigating Liquid, Ready to Use Botulinum Toxin

Galderma recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114. The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of QM1114, a liquid formulation of botulinum toxin type A, for the treatment of glabellar lines in more than 350 patients. According to a release from the company, the Phase 3 clinical trial program, which will include approximately 1,500 subjects, will begin soon to support regulatory submissions globally.

Galderma Celebrates Charitable Partnerships for Month of June

Patients undergoing treatment with Dysport during the month of June are helping to support three impactful charities thanks to a partnership between Galderma, Dress for Success, PAWS and The National Coalition Against Domestic Violence (NCADV).

Until June 30, for every Dysport aesthetic treatment administered in select markets nationwide from a licensed healthcare provider and recorded in the ASPIRE Galderma Rewards loyalty program, $25-$100 will be donated to Dress for Success, PAWS or the NCADV as follows:

Galderma Launches Joint Promotions With Top Skincare Brands

Woman looking at skin care

In an effort to encourage patient loyalty by helping practices offer science-based skincare products along with facial injectable treatments, Galderma Laboratories is collaborating with professional-grade skincare brands Revision Skincare, Alastin Skincare and Sente. This effort was inspired by the ongoing success of the company’s long-standing, ongoing collaborations with Colorescience and Mentor Breast Implants.

Results From Phase 4 Clinical Studies of Restylane Refyne and Restylane Defyne Released

Phase 4 Clinical Study Results on Restylane Refyne and Defyne

Galderma has released the results from two Phase 4 clinical studies of Restylane Refyne and Restylane Defyne, the most recent U.S. additions to it Restylane family of soft tissue fillers. The Natural Expression study found that natural facial expression was maintained in 95% (60/63) of subjects (primary objective). The Dynamic Strain study found that 83% (25/30) of subjects had enhanced attractiveness, looked younger and maintained expression following injections of Restylane Refyne and Restylane Defyne.

FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers

FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers

Galderma has received U.S. Food and Drug Administration (FDA) approval of two new Restylane products for the treatment of nasolabial folds (NLF) in patients over the age of 21. Restylane Refyne is approved for the treatment of moderate to severe facial wrinkles and folds, and Restylane Defyne for the treatment of moderate to severe, deep facial wrinkles and folds.

Restylane Turns 20

Galderma is celebrating 20 years of Restylane with new packaging and a new, more ergonomic syringe design.
Restylane Turns 20

Though silicone- and then collagen-based dermal fillers have been used since the 1940s to fill out facial defects, it was the introduction of hyaluronic acid (HA)-based dermal fillers that brought these treatments to the main­­stream. “HA fillers completely changed cosmetic medicine,” says facial plastic surgeon Steven Dayan, MD, clin­ical assistant professor at the University of Illinois. “They don’t just fill lines; they actually give volume back to the face. They also have a more natural feel than collagen and offer reversibility that is reliable.

Cetaphil Celebrates Fifth Year Supporting CSDF and Camp Wonder

Galderma Laboratories, makers of Cetaphil, is celebrating the fifth consecutive year of its “Meaningphil” partnership with the Children’s Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. What began as a product sponsorship has evolved into a long-term commitment to raising awareness of skin diseases, with Galderma and Cetaphil providing not only product, but grants, volunteers and sponsored activities as a part of their partnership with the CSDF.